This trial is testing a combination of drugs to treat patients with a certain type of lymphoma. The drugs work in different ways to stop the growth of cancer cells.
- Follicular Lymphoma
1 Primary · 7 Secondary · Reporting Duration: Up to 3 years
Side Effects for
Awards & Highlights
1 Treatment Group
Treatment (acalabrutinib, lenalidomide, rituximab)
1 of 1
24 Total Participants · 1 Treatment Group
Primary Treatment: Acalabrutinib · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 18 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the government's stance on Acalabrutinib?
"Acalabrutinib's safety is based primarily on Phase 2 trial data, which means that while there is some evidence to support its safety, there is none for its efficacy." - Anonymous Online Contributor
What is the estimated amount of people who will be participating in this research project?
"That is correct, the online clinicaltrials.gov registry indicates that this research study is actively looking for participants. The trial was first advertised on 16/7/2020 and underwent its most recent update on 31/7/2022. In total, the investigators seek to enroll 24 individuals at a single medical facility." - Anonymous Online Contributor
Are applications for this research being accepted at the moment?
"Yes, this study is still recruiting patients. The listing on clinicaltrials.gov shows that the trial was posted on July 16th 2020 and updated as recently as July 31st, 2022." - Anonymous Online Contributor
What are some of the primary benefits of Acalabrutinib?
"Acalabrutinib is a medication used to treat chronic lymphocytic leukemia, but it can also help patients with diffuse large b-cell lymphoma (dlbcl) and kidney failure. If you have had two prior systemic chemotherapy regimens, this drug may be right for you." - Anonymous Online Contributor